Chinese patent medicine: Opening new perspectives for treatment of post-endoscopic submucosal dissection esophageal stricture in esophageal cancer patients  

作　　者：Jie-Yu Guo Xue-Ying Dong Shi Li Jing-Feng Tang Ce-Fan Zhou 

机构地区：[1]School of Life and Health Sciences,Institute of Biomedical Research,Wuhan 430068,Hubei Province,China [2]National"111"Center for Cellular Regulation and Molecular Pharmaceutics,School of Life and Health Sciences,Key Laboratory of Fermentation Engineering(Ministry of Education),Hubei University of Technology,Wuhan 430068,Hubei Province,China

出　　处：《World Journal of Gastroenterology》2025年第14期157-160,共4页世界胃肠病学杂志(英文)

基　　金：Supported by National Natural Science Foundation of China,No.82370715,No.32270768,and No.82273970;National Key R and D Program of China,No.2023YFC2507904;Innovation Group Project of Hubei Province,No.2023AFA026.

摘　　要：Endoscopic submucosal dissection(ESD)is an effective technique for treating early esophageal cancer,and the prevention of postoperative esophageal stricture has emerged as a significant research topic.Zhou et al utilized an experimental minipig model to demonstrate that Kangfuxin(KFX)can improve postoperative esophageal stricture following ESD by inhibiting transforming growth factor-β1-driven fibrosis and the downstream fibrotic mediators Smad2/3.In this letter,we primarily discuss recent advancements in the treatment of esophageal stricture,the clinical applications of KFX,and the mechanisms involved in alleviating postoperative esophageal stricture,aiming to provide insights for advancing clinical practice and research in esophageal stricture after ESD.

关 键 词：Post-endoscopic submucosal dissection Esophageal stricture KANGFUXIN Transforming growth factor-β1 SMAD2/3 

分 类 号：R735.1[医药卫生—肿瘤]